Virus-like particles: The new frontier of vaccines for animal viral infections

被引:110
|
作者
Crisci, Elisa [1 ]
Barcena, Juan [2 ]
Montoya, Maria [1 ,3 ]
机构
[1] UAB IRTA, Ctr Recerca Sanitat Anim CReSA, Barcelona 08193, Spain
[2] Ctr Invest Sanidad Anim CISA INIA, Madrid 28130, Spain
[3] IRTA, Barcelona, Spain
关键词
Virus-like particles (VLPs); Animal vaccines; Vaccine vectors; RABBIT HEMORRHAGIC-DISEASE; PORCINE CIRCOVIRUS TYPE-2; PARVOVIRUS-LIKE PARTICLES; ROTAVIRUS-LIKE PARTICLES; TOBACCO-MOSAIC-VIRUS; T-CELL RESPONSES; IMMUNE-RESPONSES; CAPSID PROTEIN; PROTECTIVE IMMUNITY; CANINE PARVOVIRUS;
D O I
10.1016/j.vetimm.2012.04.026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:211 / 225
页数:15
相关论文
共 50 条
  • [41] GENETICALLY-ENGINEERED MULTICOMPONENT VIRUS-LIKE PARTICLES AS VETERINARY VACCINES
    PEARSON, LD
    ROY, P
    IMMUNOLOGY AND CELL BIOLOGY, 1993, 71 : 381 - 389
  • [42] Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines
    Norizwan, Jaffar Ali Muhamad
    Tan, Wen Siang
    CURRENT RESEARCH IN MICROBIAL SCIENCES, 2025, 8
  • [43] Structures of virus and virus-like particles
    Johnson, JE
    Chiu, V
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2000, 10 (02) : 229 - 235
  • [44] Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design
    Plummer, Emily M.
    Manchester, Marianne
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2011, 3 (02) : 174 - 196
  • [45] VIRUS-LIKE PARTICLES IN LIVER OF PATIENTS WITH ACUTE VIRAL-HEPATITIS
    PEREZ, V
    VANNYNAT.B
    MAURO, EL
    MARUFFO, CA
    MEDICINA-BUENOS AIRES, 1973, 33 (02) : 145 - 149
  • [46] Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections
    Swenson, DL
    Warfield, KL
    Negley, DL
    Schmaljohn, A
    Aman, MJ
    Bavari, S
    VACCINE, 2005, 23 (23) : 3033 - 3042
  • [47] Influenza virus-like particle vaccines
    Haynes, Joel R.
    EXPERT REVIEW OF VACCINES, 2009, 8 (04) : 435 - 445
  • [48] New plant virus-like particles: Construction and characterization
    Balke, Ina
    Resevica, Gunta
    Kalnciema, Ieva
    Zeltina, Vilija
    Ose, Velta
    Zeltins, Andris
    JOURNAL OF BIOTECHNOLOGY, 2016, 231 : S10 - S10
  • [49] Virus-like particles as immunogens
    Noad, R
    Roy, P
    TRENDS IN MICROBIOLOGY, 2003, 11 (09) : 438 - 444
  • [50] Virus-like particles as vaccine
    Chroboczek, Jadwiga
    Szurgot, Inga
    Szolajska, Ewa
    ACTA BIOCHIMICA POLONICA, 2014, 61 (03) : 531 - 539